Company news
Emyria Ltd news in 2021
Emyria Ltd's news releases, calls and decks from 2021, newest first.
Notification regarding unquoted securities - EMD
December 30, 2021
Emyria adds wearables to psychedelic-assisted therapy trials
December 19, 2021
Pause in Trading
December 15, 2021
Positive animal data for Emyrias ultra-pure CBD capsule
December 14, 2021
Positive initial MDMA-analogue screening results
December 7, 2021
Emyria receives $1,162,000 R&D Tax Incentive Refund
November 23, 2021
Emyria Welcomes Tattarang as Strategic Investor
November 21, 2021
MDMA Analogue Development Milestone
October 18, 2021
Emyria selected to join Palantirs Foundry Builders Program
October 6, 2021
Novel MDMA Analogue Screening Program Advanced
September 21, 2021
Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
September 15, 2021
MDMA-analogues Show Promise for Parkinsons Disease
August 31, 2021
Emyria Engages Calvert Labs for Preclinical CBD studies
August 26, 2021
Emyria Appoints Expert Neuropharmacologist for MDMA Program
August 19, 2021
Emyria Executes Pure CBD Agreement with AltaSciences
August 12, 2021
Emyria to Develop Novel Psychedelics Pipeline with UWA
August 4, 2021
Emyria Advances EMD-004 Program Towards Registration
June 14, 2021
Emyria Data Validated, Care Model Reduces Opioids
June 6, 2021
Emyria Obtains TGA Approval for Medical Grade Monitoring App
May 12, 2021
Emyria and MMA launch MDMA-assisted therapy program for PTSD
May 4, 2021
$5m Placement for Drug Registration and Treatment Pipeline
April 21, 2021
Emyria and Cann Partner to Register CBD Product
March 28, 2021
Emyria Adds Second Clinical Site in Perth
March 1, 2021
Emyria adds second Emerald Clinic in Melbourne
February 9, 2021
Emyria wins digital health monitoring grant with UWA
February 4, 2021
FDA Position on RWE to Guide Registration
January 26, 2021
Emyria Pursuing Registration of EMD-003 in CY2021
January 4, 2021
Decks in 2021
- Share Café June 2021 "Hidden Gems": medicinal cannabis/hemp Webinar
Conference · 25 slides · Jun 18, 2021